PRX 00023

Known as: PRX-00023, PRX00023 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2009
01220052009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
To address the development of early anxiety disorders across the lifespan, the High USV line of rats was bred based on rates of… (More)
Is this relevant?
2008
2008
PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the… (More)
Is this relevant?
2008
2008
BACKGROUND The serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor likely plays a critical role in anxiety pathophysiology… (More)
  • table II
Is this relevant?
2007
2007
PRX-00023 is a novel, nonazapirone 5-HT1A agonist in clinical development for treatment of affective disorders. The objectives of… (More)
Is this relevant?
Review
2007
Review
2007
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… (More)
Is this relevant?
2005
2005
Peroxiredoxins (Prxs) are expressed in the epidermis, and the accentuated expression of the Prx I and Prx II isotypes (Prx I/II… (More)
  • figure 2
  • figure 1
  • figure 3
Is this relevant?